Publications by authors named "Steve Knapper"

Claim this Profile
P
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
Andrew M Brunner, Jordi Esteve, Kimmo Porkka, Steve Knapper, Elie Traer

Am J Hematol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.
Donal P McLornan, Anna L Godfrey, Anna Green, Rebecca Frewin, Siamak Arami, Steve Knapper

Br J Haematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The management of myelofibrosis: A British Society for Haematology Guideline.
Donal P McLornan, Bethan Psaila, Joanne Ewing, Andrew Innes, Siamak Arami, Steve Knapper

Br J Haematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.
Jad Othman, Charlotte Wilhelm-Benartzi, Richard Dillon, Steve Knapper, Sylvie D Freeman

Blood Adv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes.
Justin Loke, Vinit Upasani, Charlotte Gaskell, Sonia Fox, Rachel Fletcher, Steve Knapper

Br J Haematol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia.
Namrata Rastogi, Juan Bautista Menendez Gonzalez, Vikas Kumar Srivastava, Bader Alanazi, Rehab N Alanazi, Steve Knapper

Leukemia· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations for laboratory testing of UK patients with acute myeloid leukaemia.
Priyanka Mehta, Nick Telford, Chris Wragg, Richard Dillon, Sylvie Freeman, Steve Knapper

Br J Haematol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial.
Richard Dillon, Shanna Maycock, Aimee Jackson, Sonia Fox, Sylvie Freeman, Steve Knapper

BMC Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein Kinase C Epsilon Overexpression Is Associated With Poor Patient Outcomes in AML and Promotes Daunorubicin Resistance Through p-Glycoprotein-Mediated Drug Efflux.
Rachael Nicholson, Ana Catarina Menezes, Aleksandra Azevedo, Adam Leckenby, Sara Davies, Steve Knapper

Front Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia.
Thomas Coats, Daniel Bean, Aymeric Basset, Tamir Sirkis, Jonathan Brammeld, Steve Knapper

Br J Haematol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia.
Joanna Zabkiewicz, Michelle Lazenby, Gareth Edwards, Ceri A Bygrave, Nader Omidvar, Steve Knapper

Br J Haematol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial.
Alan K Burnett, Emma Das Gupta, Steve Knapper, Asim Khwaja, Marion Sweeney

Haematologica· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia.
Naeem Khan, Robert K Hills, Steve Knapper, Lora Steadman, Ushna Qureshi

PLoS One· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series.
Yan Beauverd, Deepti Radia, Catherine Cargo, Steve Knapper, Mark Drummond

Haematologica· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Alan K Burnett, Nigel H Russell, Robert K Hills, David Bowen, Jonathan Kell, Steve Knapper

Lancet Oncol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia.
Nicolas Goardon, Emanuele Marchi, Ann Atzberger, Lynn Quek, Anna Schuh, Steve Knapper

Cancer Cell· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting treatment in AML.
Alan K Burnett, Steve Knapper

Hematology Am Soc Hematol Educ Program· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis